Hepatitis C in an Urban Cohort: Who's not being treated?

Journal of Health Care for the Poor and Underserved

Volumn 20, Issue 4, 2009, Pages 1068-1078

  Alfandre, David ^a,b   Gardenier, Donald ^c   Federman, Alex ^c   McGinn, Thomas ^d  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Department of Medicine ^*

Author keywords

Hepatitis C; Treatment; Underserved

Indexed keywords

ARTICLE; COHORT ANALYSIS; COMORBIDITY; ETHNOLOGY; FEMALE; GENETICS; GENOTYPE; HEALTH SERVICE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT REFERRAL; PRIMARY HEALTH CARE; RETROSPECTIVE STUDY; STATISTICS; TREATMENT REFUSAL; UNITED STATES;

COHORT STUDIES; COMORBIDITY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW YORK CITY; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; TREATMENT REFUSAL; URBAN HEALTH SERVICES;

EID: 74349104145     PISSN: 10492089     EISSN: None     Source Type: Journal    
DOI: 10.1353/hpu.0.0203     Document Type: Article

References (45)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5;345(1): 41-52.
2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006 May 16; 144(10):705-14.
3. Sturm T, Wisnivesky J. Hepatitis C prevalence and risk factors in an urban primary care practice. J Gen Intern Med. 2004;19(Suppl 1):157.
4. Briggs ME, Baker C, Hall R, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology. 2001 Dec;34(6):1200-5.
5. Management of hepatitis C. NIH Consens Statement. 1997 Mar 24-26;15(3):1-41. Review.
6. Hepatitis C. Ann Intern Med. 2008 Jun;148(11):ITC6-1.
7. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997 Nov 15; 127(10):875-81.
8. Schackman BR, Teixeira PA, Beeder AB. Offers of hepatitis C care do not lead to treatment. J Urban Health. 2007 May;84(3):455-8.
9. Shatin D, Schech SD, Patel K, et al. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care. 2004 Apr; 10(4):250-6.
10. Witkos M, Yi QL, Heathcote J, et al. Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. Can J Gastroenterol. 2006 Feb;20(2):107-11.
11. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002 Feb 19;136(4):288-92.
12. Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci. 2007 Nov;52(11):3251-8. Epub 2007 Mar 30.
13. Geppert CM, Arora S. Ethical issues in the treatment of hepatitis C. Clin Gastroenterol Hepatol. 2005 Oct;3(10):937-44.
14. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003 May;124(6):1711-9. Review.
15. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005 Aug;20(8):754-8.
16. Hare CB, Morris JA, Chu A, et al. Comparison of characteristics of treated and non- treated patients with hepatitis C infection. Pharmacoepidemiol Drug Saf. 2006 Feb; 15(2):71-6.
17. Markowitz JS, Gutterman EM, Hodes D, et al. Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. J Viral Hepat. 2005 Mar;12(2):176-85.
18. Chainuvati S, Khalid SK, Kancir S, et al. Comparison of hepatitis C treatment pat terns in patients with and without psychiatric and/or substance use disorders. J Viral Hepat. 2006 Apr;13(4):235-41.
19. McGinn TG, Gardenier D, McGinn LK, et al. Treating chronic hepatitis C in the primary care setting. Semin Liver Dis. 2005 Feb;25(1):65-71.
20. Gardenier D, Neushotz LA, O'Connor-Moore N. Medical/psychiatric comanagement by nurse practitioners in chronic hepatitis C treatment: a case study. Arch Psychiatr Nurs. 2007 Apr;21(2):87-90.
21. Strader DB, Wright T, Thomas DL, et al. Diagnosis management and treatment of hepatitis C. Hepatology. 2004 Apr:39(4)1147-71.
22. American Psychiatric Assocation. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (4th ed.). Arlington, VA: American Psychiatric Publishing, 1994.
23. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.
24. Mineau GP, Smith KR, Bean LL. Historical trends of survival among widows and widowers. Soc Sci Med. 2002 Jan;54(2):245-54.
25. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993 Dec;138(11):923-36.
26. Cawthorne CH, Rudat KR, Burton MS, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol. 2002 Jan;97(1):149-55.
27. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology. 1997 Dec;26(3):2S-10S.
28. McNally S, Temple-Smith M, Sievert W, et al. Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Public Health. 2006 Oct;30(5):422-7.
29. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999 Oct 20;282(15):1458-65. Review.
30. Hamilton HE, Nelson M, Martin P, et al. Provider-patient in-office discussions of response to hepatitis C antiviral therapy and impact on patient comprehension. Clin Gastroenterol Hepatol. 2006 Apr;4(4):507-13.
31. Fraenkel L, McGraw S, Wongcharatrawee S, et al. What do patients consider when making decisions about treatment for hepatitis C? Am J Med. 2005 Dec;118(12): 1387-91.
32. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci. 2007 May;52(5):1168-76. Epub 2007 Mar 15.
33. Moirand R, Bilodeau M, Brissette S, et al. Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage. Can J Gastroenterol. 2007 Jun;21(6):355-61.
34. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. weeks in HCV genotype 2 or 3. N Engl J Med. 2005 Jun 23;352(25):2609-17.
35. Akay S, Karasu Z, Noyan A, et al. Liver biopsy: is the pain for real or is it only the fear of it? Dig Dis Sci. 2007 Feb;52(2):579-81. Epub 2007 Jan 9.
36. Eisenberg E, Konopniki M, Veitsman E, et al. Prevalence and characteristics of pain induced by percutaneous liver biopsy. Anesth Analg. 2003 May;96(5):1392-6, table of contents.
37. Markowitz JS, Gutterman EM, Hodes D, et al. Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. J Viral Hepat. 2005 Mar;12(2):176-85.
38. Andriulli A, Persico M, Iacobellis A, et al. Treatment of patients with HCV infection with or without liver biopsy. J Viral Hepat. 2004 Nov;11(6):536-42.
39. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007 Mar;56(3):385-9. Epub 2006 Sep 27.
40. McGinn TG, Gardenier D, McGinn LK, et al. Treating chronic hepatitis C in the primary care setting. Semin Liver Dis. 2005 Feb;25(1):65-71.
41. Blasiole JA, Shinkunas L, Labrecque DR, et al. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol. 2006 Aug;12(29):4665-72.
42. Patel SS, Peterson RA, Kimmel PL. The impact of social support on end-stage renal disease. Semin Dial. 2005 Mar-Apr;18(2):98-102.
43. Eriksen W. The role of social support in the pathogenesis of coronary heart disease. A literature review. Fam Pract. 1994 Jun;11(2):201-9.
44. Berkman LF. The role of social relations in health promotion. Psychosom Med. 1995 May-Jun;57(3):245-54.
45. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997 Sep;26(3 Suppl 1): 62S-65S.